NCT02336165 2022-10-12Phase 2 Study of Durvalumab (MEDI4736) in Patients With GlioblastomaLudwig Institute for Cancer ResearchPhase 2 Completed159 enrolled 23 charts
NCT02794883 2022-04-18Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant GliomaNorthwestern UniversityPhase 2 Completed36 enrolled 13 charts